Improved therapeutic potential of MSCs by genetic modification
- 25 September 2018
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 25 (8) , 538-547
Abstract
Mesenchymal stem cells (MSCs), well-studied adult stem cells in various tissues, possess multi-lineage differentiation potential and anti-inflammatory properties. MSCs have been approved to regenerate lineage-specific cells to replace injured cells in tissues. MSCs are approved to treat inflammatory diseases. With the discovery of genes important for the repair of damaged tissues, MSCs genetically modified by such genes hold improved therapeutic potential. In this review, we summarised the uses of genetically modified MSCs to treat different diseases, including bone diseases, cardiovascular diseases, autoimmune diseases, central nervous system disorders, and cancer. To better understand the exact role of genetically modified MSCs, key mechanisms determining, which genes are selected to be used for modifying MSCs and improvements in post-genetic modification are discussed. Therapeutic benefits enhanced by genetic modifications are to be documented by further clinical studies.Keywords
This publication has 85 references indexed in Scilit:
- Hepatocyte growth factor/ c-met signaling is required for stem-cell–mediated liver regeneration in miceHepatology, 2011
- Hypoxia-inducible Vascular Endothelial Growth Factor-engineered Mesenchymal Stem Cells Prevent Myocardial Ischemic InjuryMolecular Therapy, 2011
- Genetically Modified Mesenchymal Stem Cells Induce Mechanically Stable Posterior Spine FusionTissue Engineering Part A, 2010
- Radiation Increases Invasion of Gene-Modified Mesenchymal Stem Cells into TumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Brain-derived neurotrophic factor released from engineered mesenchymal stem cells attenuates glutamate- and hydrogen peroxide-mediated death of staurosporine-differentiated RGC-5 cellsExperimental Eye Research, 2009
- Therapeutic potential of genetically modified adult stem cells for osteopeniaGene Therapy, 2009
- The metastatic niche: adapting the foreign soilNature Reviews Cancer, 2009
- Bipartite Adenoviral Vector Encoding hHGF and hIL-1Ra for Improved Human Islet TransplantationPharmaceutical Research, 2008
- Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repairProceedings of the National Academy of Sciences, 2007
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003